Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals. It is grouped under the following drug class(es): Angiotensin II Receptor Blockers (ARBs). Its therapeutic use is listed as antihypertensives and cardiovascular. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include FImasartanum and Kanarb. Its PubChem CID is 9870652.
Fimasartan
| CAS No | 247257-48-3 |
|---|---|
| Molecular Formula | C27H31N7OS |
| Molecular Weight | 501.6 g/mol |
| Synonyms | 2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.
The listed CAS number is 247257-48-3.
The listed molecular formula is C27H31N7OS.
The listed molecular weight is 501.6 g/mol.
2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide.
The source lists FImasartanum and Kanarb.